Recent PAVM Stock Price | PAVM Stock Predictions | |
$2.19 | +196.80% |
$6.50 |
Recent PAVM Analyst Ratings Breakdown, Making PAVM Stock Predictions | ||||
---|---|---|---|---|
Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
Strong buy ratings: | 1 | 1 | 1 | 1 |
Buy ratings: | 0 | 0 | 0 | 0 |
Hold ratings: | 1 | 1 | 1 | 1 |
Sell ratings: | 0 | 0 | 0 | 0 |
Strong sell ratings: | 0 | 0 | 0 | 0 |
Average rating: | 2.0 | 2.0 | 2.0 | 2.0 |
For the PAVM stock predictions from the analysts covering PAVmed Inc, we have collected all of the individual PAVM stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the 2 different analysts covering PAVM (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since PAVM stock predictions may vary widely, another useful metric to consider is the median PAVM stock prediction, which represents the price at which half of the analysts
made PAVM stock predictions that were higher and half made PAVM stock predictions that were lower. This makes for a different take on the PAVM stock predictions out there, as compared to average or mean.
And that median across all the individual PAVM stock predictions was: $6.5 as of 2024-05-07.
The very highest of the PAVM stock predictions for one year price target was $9.0, while the very lowest of the PAVM stock predictions in the analyst group was
$4.0 (with a standard deviation of $3.535). Get the latest Zacks research report on PAVM — FREE
Find out: PAVM next earnings date »
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
TPRE Stock Predictions
HARP Stock Predictions
RKT Stock Predictions
MLAB Stock Predictions
ZUO Stock Predictions
MG Stock Predictions
WHR Stock Predictions
GBCI Stock Predictions
RGNX Stock Predictions
|
|
Buy (3.00 out of 4) 32nd percentile
(ranked lower than approx. 68% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |